FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:694-705 February 12, 2004 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In 1993 the Diabetes Control and Complications Trial (DCCT) established the modern standard of care for the medical management of type 1 diabetes mellitus.¹ The DCCT randomly assigned 1441 patients to conventional or intensive treatment. The latter included multiple daily determinations of blood glucose levels at home by finger stick; combinations of daily injections of long-, intermediate-, and short-acting insulin; and dietary and psychological support. The clinical outcomes in terms of secondary complication rates were much better in the intensively treated group than in the conventionally treated group; thereafter, intensive treatment became the norm. More recent improvements in home glucose . . . [Full Text of this Article]

History of Islet Transplantation from 1894 to 2000

Can Islet Yields Be Improved?

Is the Liver the Optimal Site for Islet Infusion?

Clinical Outcomes, 2001 to 2003

Defining Success

The Next Generation of Research Studies

Problems of Supply and Demand

Conclusions

Source Information

From the Pacific Northwest Research Institute and the Division of Metabolism, Endocrinology, and Nutrition, Departments of Medicine and Pharmacology, University of Washington School of Medicine, Seattle.

Address reprint requests to Dr. Robertson at the Pacific Northwest Research Institute, 720 Broadway, Seattle, WA 98122, or at rpr@pnri.org.

Related Letters:

Islet Transplantation as a Treatment for Diabetes
Harlan D. M., Rother K. I., Robertson R. P.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2104, May 13, 2004. Correspondence

This article has been cited by other articles:

• Harlan, D. M., Kenyon, N. S., Korsgren, O., Roep, B. O., for the Immunology of Diabetes Society, (2009). Current Advances and Travails in Islet Transplantation. Diabetes 58: 2175-2184 [Full Text]  
• Hilbrands, R., Huurman, V. A.L., Gillard, P., Velthuis, J. H.L., De Waele, M., Mathieu, C., Kaufman, L., Pipeleers-Marichal, M., Ling, Z., Movahedi, B., Jacobs-Tulleneers-Thevissen, D., Monbaliu, D., Ysebaert, D., Gorus, F. K., Roep, B. O., Pipeleers, D. G., Keymeulen, B. (2009). Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients. Diabetes 58: 2267-2276 [Abstract] [Full Text]  
• Heimberg, H. (2008). Boosting Beta-Cell Numbers. NEJM 359: 2723-2724 [Full Text]  
• Huang, X., Moore, D. J., Ketchum, R. J., Nunemaker, C. S., Kovatchev, B., McCall, A. L., Brayman, K. L. (2008). Resolving the Conundrum of Islet Transplantation by Linking Metabolic Dysregulation, Inflammation, and Immune Regulation. Endocr. Rev. 29: 603-630 [Abstract] [Full Text]  
• Meier, J. J., Butler, A. E., Saisho, Y., Monchamp, T., Galasso, R., Bhushan, A., Rizza, R. A., Butler, P. C. (2008). {beta}-Cell Replication Is the Primary Mechanism Subserving the Postnatal Expansion of {beta}-Cell Mass in Humans. Diabetes 57: 1584-1594 [Abstract] [Full Text]  
• Beith, J. L., Alejandro, E. U., Johnson, J. D. (2008). Insulin Stimulates Primary {beta}-Cell Proliferation via Raf-1 Kinase. Endocrinology 149: 2251-2260 [Abstract] [Full Text]  
• Bao, S., Jacobson, D. A., Wohltmann, M., Bohrer, A., Jin, W., Philipson, L. H., Turk, J. (2008). Glucose homeostasis, insulin secretion, and islet phospholipids in mice that overexpress iPLA2{beta} in pancreatic {beta}-cells and in iPLA2{beta}-null mice. Am. J. Physiol. Endocrinol. Metab. 294: E217-E229 [Abstract] [Full Text]  
• Robertson, R. P. (2007). Estimation of {beta}-Cell Mass by Metabolic Tests: Necessary, but How Sufficient?. Diabetes 56: 2420-2424 [Abstract] [Full Text]  
• Eich, T., Eriksson, O., Lundgren, T., the Nordic Network for Clinical Islet Transplantat, (2007). Visualization of Early Engraftment in Clinical Islet Transplantation by Positron-Emission Tomography. NEJM 356: 2754-2755 [Full Text]  
• Keymeulen, B., Gillard, P., Mathieu, C., Movahedi, B., Maleux, G., Delvaux, G., Ysebaert, D., Roep, B., Vandemeulebroucke, E., Marichal, M., In 't Veld, P., Bogdani, M., Hendrieckx, C., Gorus, F., Ling, Z., van Rood, J., Pipeleers, D. (2006). Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc. Natl. Acad. Sci. USA 103: 17444-17449 [Abstract] [Full Text]  
• Shapiro, A.M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., Cagliero, E., Alejandro, R., Ryan, E. A., DiMercurio, B., Morel, P., Polonsky, K. S., Reems, J.-A., Bretzel, R. G., Bertuzzi, F., Froud, T., Kandaswamy, R., Sutherland, D. E.R., Eisenbarth, G., Segal, M., Preiksaitis, J., Korbutt, G. S., Barton, F. B., Viviano, L., Seyfert-Margolis, V., Bluestone, J., Lakey, J. R.T. (2006). International Trial of the Edmonton Protocol for Islet Transplantation.. NEJM 355: 1318-1330 [Abstract] [Full Text]  
• Wideman, R. D., Yu, I. L. Y., Webber, T. D., Verchere, C. B., Johnson, J. D., Cheung, A. T., Kieffer, T. J. (2006). Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl. Acad. Sci. USA 103: 13468-13473 [Abstract] [Full Text]  
• Meier, J. J., Hong-McAtee, I., Galasso, R., Veldhuis, J. D., Moran, A., Hering, B. J., Butler, P. C. (2006). Intrahepatic transplanted islets in humans secrete insulin in a coordinate pulsatile manner directly into the liver.. Diabetes 55: 2324-2332 [Abstract] [Full Text]  
• Narang, A. S., Mahato, R. I. (2006). Biological and biomaterial approaches for improved islet transplantation.. Pharmacol. Rev. 58: 194-243 [Abstract] [Full Text]  
• American Diabetes Association, (2006). Pancreas and Islet Transplantation in Type 1 Diabetes. Diabetes Care 29: 935-935 [Full Text]  
• Bogdani, M., Suenens, K., Bock, T., Pipeleers-Marichal, M., In't Veld, P., Pipeleers, D. (2005). Growth and Functional Maturation of {beta}-Cells in Implants of Endocrine Cells Purified From Prenatal Porcine Pancreas. Diabetes 54: 3387-3394 [Abstract] [Full Text]  
• Bottino, R., Trucco, M. (2005). Multifaceted Therapeutic Approaches for a Multigenic Disease. Diabetes 54: S79-S86 [Abstract] [Full Text]  
• Valdes-Gonzalez, R. A, Dorantes, L. M, Garibay, G N., Bracho-Blanchet, E., Mendez, A. J, Davila-Perez, R., Elliott, R. B, Teran, L., White, D. J G (2005). Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study. Eur J Endocrinol 153: 419-427 [Abstract] [Full Text]  
• Brissova, M., Fowler, M. J., Nicholson, W. E., Chu, A., Hirshberg, B., Harlan, D. M., Powers, A. C. (2005). Assessment of Human Pancreatic Islet Architecture and Composition by Laser Scanning Confocal Microscopy. J. Histochem. Cytochem. 53: 1087-1097 [Abstract] [Full Text]  
• Warnock, G. L., Meloche, R. M., Thompson, D., Shapiro, R. J., Fung, M., Ao, Z., Ho, S., He, Z., Dai, L.-J., Young, L., Blackburn, L., Kozak, S., Kim, P. T. W., Al-Adra, D., Johnson, J. D., Liao, Y.-H. T., Elliott, T., Verchere, C. B. (2005). Improved Human Pancreatic Islet Isolation for a Prospective Cohort Study of Islet Transplantation vs Best Medical Therapy in Type 1 Diabetes Mellitus. Arch Surg 140: 735-744 [Abstract] [Full Text]  
• Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R.T., Shapiro, A.M. J. (2005). Five-Year Follow-Up After Clinical Islet Transplantation. Diabetes 54: 2060-2069 [Abstract] [Full Text]  
• Rossi, J., Santamaki, P., Airaksinen, M. S., Herzig, K.-H. (2005). Parasympathetic Innervation and Function of Endocrine Pancreas Requires the Glial Cell Line-Derived Factor Family Receptor {alpha}2 (GFR{alpha}2). Diabetes 54: 1324-1330 [Abstract] [Full Text]  
• Kaneto, H., Matsuoka, T.-a., Nakatani, Y., Miyatsuka, T., Matsuhisa, M., Hori, M., Yamasaki, Y. (2005). A Crucial Role of MafA as a Novel Therapeutic Target for Diabetes. J. Biol. Chem. 280: 15047-15052 [Abstract] [Full Text]  
• Kaneto, H., Nakatani, Y., Miyatsuka, T., Matsuoka, T.-a., Matsuhisa, M., Hori, M., Yamasaki, Y. (2005). PDX-1/VP16 Fusion Protein, Together With NeuroD or Ngn3, Markedly Induces Insulin Gene Transcription and Ameliorates Glucose Tolerance. Diabetes 54: 1009-1022 [Abstract] [Full Text]  
• Harlan, D. M., Rother, K. I., Robertson, R. P. (2004). Islet Transplantation as a Treatment for Diabetes. NEJM 350: 2104-2104 [Full Text]